☆ 4.6 Review

The Anti-Thrombotic Effects of PCSK9 Inhibitors

PHARMACEUTICALS (2023)

Related references

Note: Only part of the references are listed.

Article Cell Biology

PCSK9 Promotes Endothelial Dysfunction During Sepsis Via the TLR4/MyD88/NF-κB and NLRP3 Pathways

Longxiang Huang et al.

Summary: Increased expression of PCSK9 during sepsis activates the TLR4/MyD88/NF-κB and NLRP3 pathways, inducing inflammation, vascular endothelial dysfunction, and decreased survival rates. Inhibition of PCSK9 may be a potential clinical therapeutic target to improve vascular endothelial function in sepsis.

INFLAMMATION (2023)

Add to Collection

Article Medicine, General & Internal

The Association Between PCSK9 Inhibitor Use and Sepsis: A Systematic Review and Meta-Analysis of 20 Double-Blind, Randomized, Placebo-Controlled Trials

Zhen Zhou et al.

Summary: The aim of this study was to determine the impact of PCSK9 inhibitor use on sepsis and severe infections. The study found that there was no association between PCSK9 inhibitor use and the risk of sepsis or severe infections. These findings provide reassurance regarding the safety of PCSK9 inhibitors in patients concerned about potential drug side effects related to infections.

AMERICAN JOURNAL OF MEDICINE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: A real-world registry

Annette M. H. Galema-Boers et al.

Summary: This study found that PCSK9 antibodies are less effective in reducing LDL-C levels in women compared to men in a clinical setting. However, there were no differences in safety between genders. These findings highlight the importance of considering sex differences in PCSK9 metabolism.

ATHEROSCLEROSIS (2023)

Add to Collection

Article Pharmacology & Pharmacy

The evolving landscape of PCSK9 inhibition in cancer

Palak P. Oza et al.

Summary: Cancer is a global burden that affects premature mortality, productivity loss, healthcare expenditures, and mental health. Recent research has revealed a new role for cholesterol-lowering PCSK9 inhibitors in cancer treatment. PCSK9 is an enzyme that degrades LDL receptors, responsible for cholesterol clearance. By inhibiting PCSK9, LDL receptors are upregulated, leading to cholesterol reduction. The cholesterol-lowering effects of PCSK9 inhibitors have potential in combating cancer growth and enhancing existing anticancer therapies.

EUROPEAN JOURNAL OF PHARMACOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells

Rahayu Zulkapli et al.

Summary: This study aimed to investigate the effects of PCSK9 inhibitors on PCSK9, targeted early atherogenesis biomarkers, and monocyte binding in stimulated human coronary artery endothelial cells (HCAEC). The results showed that PCSK9 inhibitors exerted anti-atherogenic effects by downregulating PCSK9 and early atherogenesis biomarkers, as well as significantly inhibiting monocyte adhesion to endothelial cells via the NF-kappa B and eNOS pathways. These findings suggest the potential role of PCSK9 inhibitors in preventing atherosclerosis-related complications.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

The Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular Disease

Osnat Itzhaki Ben Zadok et al.

Summary: The study investigated the effect of PCSK9 inhibitors on circulating endothelial progenitor cells (cEPCs) in patients with cardiovascular disease, finding that treatment with PCSK9i resulted in higher levels of active cEPCs, promoting endothelial repair and suggesting a novel mechanism of action for PCSK9i.

CARDIOVASCULAR DRUGS AND THERAPY (2022)

Add to Collection

Article Medicine, Research & Experimental

Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players

Patrice Marques et al.

Summary: Inhibiting PCSK9 function can impact systemic inflammation and endothelial dysfunction by constraining leukocyte-endothelium interactions, enhancing T-regulatory cell activation, and reducing inflammatory response.

BIOMEDICINE & PHARMACOTHERAPY (2022)

Add to Collection

Article Oncology

Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer

Mengqing Xie et al.

Summary: A low baseline plasma PCSK9 level may predict good outcomes in patients with advanced NSCLC treated with ICIs.

THORACIC CANCER (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Short-Term Treatment with Alirocumab, Flow-Dependent Dilatation of the Brachial Artery and Use of Magnetic Resonance Diffusion Tensor Imaging to Evaluate Vascular Structure: An Exploratory Pilot Study

Thomas Metzner et al.

Summary: The study investigated the short-term effects of alirocumab on vascular function using non-invasive methods. The results showed that significant effects of short-term alirocumab treatment on vascular function were not detectable. Further research is needed to evaluate the potential value of carotid fractional anisotropy in clinical atherosclerosis research.

BIOMEDICINES (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review

Na-Qiong Wu et al.

Summary: PCSK9, in addition to lowering LDL-C levels, also plays a role in the modulation of inflammation, which may explain its reduction in cardiovascular risk. Previous studies have shown that PCSK9 is associated with inflammation, as it can induce inflammatory responses, regulate the expression of inflammatory cytokines, and interact with receptors of inflammatory mediators. The interaction between PCSK9 and LOX-1 may be involved in the inflammatory response of atherosclerosis. Understanding the relationship between PCSK9 and inflammation is crucial for the prevention and management of ASCVD.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

A novel prothrombotic role of proprotein convertase subtilisin kexin 9: the generation of procoagulant extracellular vesicles by human mononuclear cells

Valentina Scalise et al.

Summary: This study found that PCSK9 stimulation induces the release of procoagulant extracellular vesicles from human mononuclear cells and THP-1 cells, contributing to an increased prothrombotic status in patients with cardiovascular diseases.

MOLECULAR BIOLOGY REPORTS (2022)

Add to Collection

Letter Hematology

Pleiotropic effects of PCSK9-inhibition on hemostasis: Anti-PCSK9 reduce FVIII levels by enhancing LRP1 expression

Francesco Paciullo et al.

THROMBOSIS RESEARCH (2022)

Add to Collection

Article Medicine, General & Internal

Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia

Marcin Basiak et al.

Summary: The study aimed to determine the efficacy of PCSK9 inhibitors in patients with isolated hypercholesterolemia. The results showed that PCSK9 inhibitors reduced plasma levels/activity of fibrinogen, factor VII, and plasminogen activator inhibitor-1, suggesting potential benefits for patients who cannot tolerate or are contraindicated for statin use.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis

Vittoria Cammisotto et al.

Summary: PCSK9 is involved in cholesterol metabolism and plays a role in the development of atherosclerosis and atherothrombotic processes, promoting plaque formation and oxidative stress.

ANTIOXIDANTS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis

Marianna Puccini et al.

Summary: PCSK9 affects platelet function and blood coagulation. Elevated blood PCSK9 levels are associated with increased platelet reactivity and platelet count. Additionally, PCSK9 affects crucial factors in the coagulation cascade.

METABOLITES (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial

Andrei C. Sposito et al.

Summary: The addition of evolocumab to empagliflozin in individuals with T2D improves endothelial function, leading to better vascular function.

CARDIOVASCULAR DIABETOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes

Li Song et al.

Summary: This study found that high PCSK9 levels were independently associated with major adverse cardiovascular events (MACEs) in ST-segment elevation myocardial infarction (STEMI) patients with diabetes undergoing primary percutaneous coronary intervention (PCI). This association may be due to the stronger correlations between PCSK9 and inflammation and platelet activation markers in diabetic patients.

CARDIOVASCULAR DIABETOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer

Chi Chun Wong et al.

Summary: The cholesterol-uptake regulator PCSK9 drives tumourigenesis and is a therapeutic target in KRAS-mutant colorectal cancer.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Medicine, General & Internal

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall

Sabina Ugovsek et al.

Summary: PCSK9 monoclonal antibodies reduce LDL cholesterol levels and moderately decrease Lp(a) levels by upregulating LDL receptors. They also have the ability to decrease platelet aggregation and activation, increase platelet responsiveness to acetylsalicylic acid, decrease the incidence of venous thromboembolism, and play a role in reducing inflammation and improving endothelial function.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Environmental Sciences

A Systematic Review on Attenuation of PCSK9 in Relation to Atherogenesis Biomarkers Associated with Natural Products or Plant Bioactive Compounds in In Vitro Studies: A Critique on the Quality and Imprecision of Studies

Rahayu Zulkapli et al.

Summary: This systematic review investigated the attenuation of PCSK9 and atherogenesis biomarkers associated with natural products and plant bioactive compounds in in vitro studies. The review highlighted the lack of precision and validity in the included research. A total of 31 articles met the inclusion criteria and 13 different atherogenesis biomarkers related to PCSK9 were identified. The study suggests that the quality of basic science research in investigating atherogenesis biomarkers is deficient in terms of precision and validity.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)

Add to Collection

Review Cell Biology

PCSK9 Inhibition: From Current Advances to Evolving Future

Chunping Liu et al.

Summary: This article summarizes the application, preclinical studies, safety, mechanism of action, and latest research progress of PCSK9 inhibitors. It aims to provide ideas for drug research and development, as well as expand the application of PCSK9 inhibitors in other diseases.

CELLS (2022)

Add to Collection

Article Medicine, General & Internal

Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque

Michal Kosowski et al.

Summary: The aim of this study was to evaluate the effect of modern lipid-lowering therapy on the stability of atherosclerotic plaque. The results showed that alirocumab treatment significantly reduced the concentration of factors that affect plaque vulnerability, and the concentrations of these factors were higher in the group of patients about to start treatment compared to the control group.

MEDICINA-LITHUANIA (2022)

Add to Collection

Article Urology & Nephrology

Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)

Cara East et al.

Summary: In individuals receiving maintenance dialysis, alirocumab significantly reduced levels of low-density lipoprotein cholesterol and apolipoprotein B, but did not clearly decrease levels of inflammatory biomarkers. Additionally, significant reductions were seen in ceramide, sphingomyelin, and cholesterol ester levels.

KIDNEY MEDICINE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol

George N. Ioannou et al.

Summary: Under a high-cholesterol diet, Pcsk9 knockout mice exhibited increased hepatic free cholesterol and cholesterol crystals, along with more severe fibrosing steatohepatitis and a higher predisposition to liver cancer compared to wild-type mice.

HEPATOLOGY COMMUNICATIONS (2022)

Add to Collection

Article Medicine, General & Internal

PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study

A. Vecchie et al.

Summary: In this study, it was found that patients with septic shock who had lower plasma PCSK9 levels tended to experience higher mortality rates. Further studies are needed to better assess the pathophysiological role of PCSK9 in sepsis.

JOURNAL OF INTERNAL MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36

Zhiyong Qi et al.

Summary: PCSK9 in plasma directly enhances platelet activation and in vivo thrombosis by binding to platelet CD36 and activating downstream signaling pathways. PCSK9 inhibitors or aspirin can abolish the enhancing effects of PCSK9.

CIRCULATION (2021)

Add to Collection

Review Biology

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia

Piotr Peczek et al.

Summary: PCSK9 inhibitors are a novel group of hypolipidemic drugs that reduce platelet activation and synergize with other antithrombotic drugs to lower the risk of atherosclerosis in high-risk hypercholesterolemia patients.

LIFE-BASEL (2021)

Add to Collection

Review Medicine, General & Internal

PCSK9 and atherosclerosis: Looking beyond LDL regulation

Rosetta Ragusa et al.

Summary: PCSK9 is involved in regulating cholesterol homeostasis and may also be associated with vascular inflammation in atherogenesis. It is expressed by various cell types and detected inside atherosclerotic plaques, potentially playing a role in the molecular processes of atherosclerosis.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Biochemistry & Molecular Biology

PCSK9 Induces Tissue Factor Expression by Activation of TLR4/NFkB Signaling

Valentina Scalise et al.

Summary: PCSK9 induces TF expression through activation of the TLR4/NFkB signaling pathway, with TF playing an essential role in both coagulation and inflammation.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease

Alvaro Petersen-Uribe et al.

Summary: Platelets play a significant role in atherothrombosis, and this study found that they are a major source of PCSK9 in coronary artery disease (CAD). PCSK9 released by platelets contributes to platelet activation and thrombo-inflammation, with inhibition of PCSK9 showing beneficial effects in reducing these processes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Multidisciplinary Sciences

Role of PAI-1 in hepatic steatosis and dyslipidemia

Joshua A. Levine et al.

Summary: PAI-1 is not only a functional biomarker of the metabolic syndrome, but also a critical regulator of hepatic lipid metabolism. By directly regulating the transcriptional expression of genes involved in lipid balance, PAI-1 plays a key role in ameliorating hyperlipidemia in vivo.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

Proprotein Convertase Subtilisin/Kexin Type 9 Promotes Gastric Cancer Metastasis and Suppresses Apoptosis by Facilitating MAPK Signaling Pathway Through HSP70 Up-Regulation

Beili Xu et al.

Summary: This study demonstrates that high expression of PCSK9 in gastric cancer tissues is associated with tumor progression and poor prognosis. PCSK9 promotes gastric cancer metastasis and suppresses apoptosis through facilitating the MAPK signaling pathway via upregulation of HSP70. PCSK9 may serve as a potential therapeutic target in gastric cancer.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Cell Biology

Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling

Juanjuan Yuan et al.

Summary: The study reveals the crucial role of LDLR in regulating the antitumor activity of CD8(+) T cells, including promoting T cell priming and clonal expansion, as well as regulating TCR signaling through interaction with the TCR complex. Moreover, the tumor microenvironment suppresses LDLR and TCR signaling in CD8(+) T cells via PCSK9, inhibiting the effector function of CTLs.

PROTEIN & CELL (2021)

Add to Collection

Article Physiology

Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes

Susanne Rohrbach et al.

Summary: PCSK9 affects LRP1-mediated signaling pathways in cardiomyocytes, influencing the metabolic effects of CTRP9, which is the CTRP with the highest homology to adiponectin. Knockdown of LRP1 reduces the cellular effects induced by CTRP9.

FRONTIERS IN PHYSIOLOGY (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 and Major Adverse Cardiovascular Events, Stroke, and All-Cause Mortality: Systemic Review and Meta-Analysis

Yimo Zhou et al.

Summary: This meta-analysis found a significant association between high circulating PCSK9 concentration and the risk of MACEs, with a linear dose-response relationship observed. However, no significant correlation was found with stroke or all-cause mortality. Further well-designed studies are needed to explore the relationships between PCSK9 concentration and stroke and mortality.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Pleiotropic Effects of PCSK-9 Inhibitors

Marcin Basiak et al.

Summary: PCSK-9 inhibitors are a group of drugs that reduce the degradation of LDL-R, increase the uptake of LDLc, and have various pleiotropic effects beyond lipid-lowering, including anti-atherosclerotic, anti-aggregation, anticoagulant, antineoplastic effects, and influence on bacterial infections. This review article systematically examines the current scientific data on the multifaceted effects of PCSK-9 inhibitors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation

Aureli Luquero et al.

Summary: The role of PCSK9 in atherosclerosis progression involves mechanisms such as lipid-lowering effects, regulation of key receptors in macrophages, and modulation of vascular inflammation. Inhibition of PCSK9 activity has been shown to reduce the progression of atherosclerotic disease.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer

Anindita Bhattacharya et al.

Summary: PCSK9 has emerged as a novel pharmacological target for hypercholesterolemia and associated cardiovascular diseases, and its aberrant expression in a broad spectrum of cancers suggests its potential as a valuable biomarker and therapeutic target in personalized cancer medicine.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways

Vittoria Cammisotto et al.

Summary: PCSK9i treatment reduces levels of LDL cholesterol, oxidized LDL, platelet activation, etc., by modulating NOX2 activity and reducing formation of oxidized LDL in patients with HeFH.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

PCSK9 Biology and Its Role in Atherothrombosis

Cristina Barale et al.

Summary: PCSK9 plays a key role in lipoprotein metabolism and atherosclerosis, with potential cardiovascular benefits from its inhibition. Currently, anti-PCSK9 antibodies and small interfering RNA are effective therapies to reduce LDL-C levels and attenuate cardiovascular disease.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology

Sai Sahana Sundararaman et al.

Summary: PCSK9, primarily secreted by hepatocytes, plays a role in regulating the degradation of the LDL receptor. Its effects on cardiovascular complications are not only LDLR-related, but also involve other independent pathways and processes.

BIOMEDICINES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach

Alessandro Di Minno et al.

Summary: Utilizing untargeted metabolomics, our study demonstrated a significant reduction in LDL-cholesterol levels in FH patients after 12 weeks of treatment with PCSK9i, along with concomitant decreases in inflammation and platelet activation metabolites.

BIOMEDICINES (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up

Cristina Barale et al.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

Jan Boren et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

Vera A. Bittner et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

Could PCSK9 be a new therapeutic target of Eugenol? In vitro and in silico evaluation of hypothesis

Saadiya Zia et al.

MEDICAL HYPOTHESES (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism

Nicholas A. Marston et al.

CIRCULATION (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?

Barbara Cybulska et al.

PROGRESS IN CARDIOVASCULAR DISEASES (2020)

Add to Collection

Article Biochemistry & Molecular Biology

PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation

Vittoria Cammisotto et al.

ANTIOXIDANTS (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study

Nicola Ferri et al.

ATHEROSCLEROSIS (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia

Thorsten M. Leucker et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)

Add to Collection

Review Neurosciences

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders

Emma M. O'Connell et al.

FRONTIERS IN NEUROSCIENCE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study

Jia Peng et al.

CARDIOVASCULAR DIABETOLOGY (2020)

Add to Collection

Article Hematology

Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy

Alessandro Di Minno et al.

THROMBOSIS RESEARCH (2020)

Add to Collection

Editorial Material Urology & Nephrology

Kidney-derived PCSK9-a new driver of hyperlipidemia in nephrotic syndrome?

Ferruh Artunc

KIDNEY INTERNATIONAL (2020)

Add to Collection

Article Medicine, Research & Experimental

Dyslipidemia induced inflammatory status, platelet activation and endothelial dysfunction in rabbits: Protective role of 10-Dehydrogingerdione

Mohamed Mahmoud El-Seweidy et al.

BIOMEDICINE & PHARMACOTHERAPY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

KLF2 regulates eNOS uncoupling via Nrf2/HO-1 in endothelial cells under hypoxia and reoxygenation

WeiDang Wu et al.

CHEMICO-BIOLOGICAL INTERACTIONS (2019)

Add to Collection

Article Multidisciplinary Sciences

Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice

Susanne Schuster et al.

SCIENTIFIC REPORTS (2019)

Add to Collection

Article Cell & Tissue Engineering

Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection

Jerome Caron et al.

STEM CELL RESEARCH & THERAPY (2019)

Add to Collection

Letter Cardiac & Cardiovascular Systems

PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers

Renate M. Hoogeveen et al.

JACC-CARDIOVASCULAR IMAGING (2019)

Add to Collection

Article Hematology

High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor

I. M. Rietveld et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)

Add to Collection

Review Hematology

PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention

Francesco Paciullo et al.

THROMBOSIS AND HAEMOSTASIS (2019)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake

Charalambos Vlachopoulos et al.

JACC-CARDIOVASCULAR IMAGING (2019)

Add to Collection

Review Cardiac & Cardiovascular Systems

Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables

Theodosios D. Filippatos et al.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2018)

Add to Collection

Article Biochemistry & Molecular Biology

New Insight on a Combination of Policosanol and 10-Dehydrogingerdione Phytochemicals as Inhibitors for Platelet Activation Biomarkers and Atherogenicity Risk in Dyslipidemic Rabbits: Role of CETP and PCSK9 Inhibition

Mohamed Mahmoud Elseweidy et al.

APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy

Aruna D. Pradhan et al.

CIRCULATION (2018)

Add to Collection

Review Peripheral Vascular Disease

Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation

Angelos D. Karagiannis et al.

CURRENT ATHEROSCLEROSIS REPORTS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Improved endothelial function after short-term therapy with evolocumab

Guglielmo Maulucci et al.

JOURNAL OF CLINICAL LIPIDOLOGY (2018)

Add to Collection

Article Hematology

Oxidized low-density lipoprotein in inflammation-driven thrombosis

G. Obermayer et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)

Add to Collection

Article Multidisciplinary Sciences

PCSK9 induces a pro-inflammatory response in macrophages

Chiara Ricci et al.

SCIENTIFIC REPORTS (2018)

Add to Collection

Article Multidisciplinary Sciences

Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor

Peter M. Grin et al.

SCIENTIFIC REPORTS (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial

Konstantinos C. Koskinas et al.

CLINICAL CARDIOLOGY (2018)

Add to Collection

Article Oncology

A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition

Jian'an Bai et al.

ONCOTARGET (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia

Sophie J. Bernelot Moens et al.

EUROPEAN HEART JOURNAL (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study

Eliano P. Nayarese et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation

Daniele Pastori et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)

Add to Collection

Article Oncology

Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis

Jiao Li et al.

MOLECULAR MEDICINE REPORTS (2017)

Add to Collection

Article Multidisciplinary Sciences

Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice

Hui Wang et al.

SCIENTIFIC REPORTS (2017)

Add to Collection

Article Microbiology

Diminished neutrophil extracellular trap (NET) formation is a novel innate immune deficiency induced by acute ethanol exposure in polymicrobial sepsis, which can be rescued by CXCL1

Liliang Jin et al.

PLOS PATHOGENS (2017)

Add to Collection

Article Hematology

Endothelial Functions

Shigeo Godo et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subtractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)

Amos Baruch et al.

AMERICAN JOURNAL OF CARDIOLOGY (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prognostic value of PCSK9 levels in patients with acute coronary syndromes

Baris Gencer et al.

EUROPEAN HEART JOURNAL (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study

Wuxiang Xie et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)

Add to Collection

Article Pharmacology & Pharmacy

Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: A case report

Shuichi Nagashima et al.

JOURNAL OF CLINICAL LIPIDOLOGY (2016)

Add to Collection

Article Immunology

Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis

John H. Boyd et al.

JOURNAL OF INNATE IMMUNITY (2016)

Add to Collection

Article Critical Care Medicine

DIFFERENTIAL EXPRESSION OF PCSK9 MODULATES INFECTION, INFLAMMATION, AND COAGULATION IN A MURINE MODEL OF SEPSIS

Dhruva J. Dwivedi et al.

SHOCK (2016)

Add to Collection

Article Multidisciplinary Sciences

LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers

Eguzkine Ochoa et al.

PLOS ONE (2016)

Add to Collection

Article Hematology

PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver

Annie Demers et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cross-talk between LOX-1 and PCSK9 in vascular tissues

Zufeng Ding et al.

CARDIOVASCULAR RESEARCH (2015)

Add to Collection

Article Peripheral Vascular Disease

The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients with Stable Coronary Artery Disease

Sha Li et al.

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2015)

Add to Collection

Article Medicine, General & Internal

Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches

Kyoung-Ha Park et al.

JOURNAL OF KOREAN MEDICAL SCIENCE (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

Daniel Gaudet et al.

AMERICAN JOURNAL OF CARDIOLOGY (2014)

Add to Collection

Review Cardiac & Cardiovascular Systems

PCSK9: A Key Modulator of Cardiovascular Health

Nabil G. Seidah et al.

CIRCULATION RESEARCH (2014)

Add to Collection

Article Endocrinology & Metabolism

Beginning to Understand High-Density Lipoproteins

Carlos G. Santos-Gallego et al.

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2014)

Add to Collection

Article Pharmacology & Pharmacy

Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease

Yan Zhang et al.

JOURNAL OF CLINICAL LIPIDOLOGY (2014)

Add to Collection

Review Medicine, General & Internal

Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia

Nabil A. Elshourbagy et al.

MEDICAL PRINCIPLES AND PRACTICE (2014)

Add to Collection

Article Pharmacology & Pharmacy

Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment

Christian Werner et al.

VASCULAR PHARMACOLOGY (2014)

Add to Collection

Article Multidisciplinary Sciences

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

Maryssa Canuel et al.

PLOS ONE (2013)

Add to Collection

Article Cardiac & Cardiovascular Systems

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

Nicola Ferri et al.

ATHEROSCLEROSIS (2012)

Add to Collection

Review Hematology

Elevated factor VIII levels and risk of venous thrombosis

P. Vince Jenkins et al.

BRITISH JOURNAL OF HAEMATOLOGY (2012)

Add to Collection

Article Cardiac & Cardiovascular Systems

Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice

Maxime Denis et al.

CIRCULATION (2012)

Add to Collection

Article Biochemistry & Molecular Biology

The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway

Yascara Grisel Luna Saavedra et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2012)

Add to Collection

Article Oncology

Tumor Microenvironment-Derived Proteins Dominate the Plasma Proteome Response during Breast Cancer Induction and Progression

Sharon J. Pitteri et al.

CANCER RESEARCH (2011)

Add to Collection

Article Hematology

Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans

Lena Persson et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)

Add to Collection

Article Cardiac & Cardiovascular Systems

Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population

Qin Cui et al.

ATHEROSCLEROSIS (2010)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

The Mysteries of Lipoprotein(a) and Cardiovascular Disease Revisited

Stefan Kiechl et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)

Add to Collection

Article Biochemistry & Molecular Biology

PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion

Cedric Langhi et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)

Add to Collection

Article Multidisciplinary Sciences

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

Da-Wei Zhang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

Add to Collection

Article Gastroenterology & Hepatology

The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus

Sonia Molina et al.

JOURNAL OF HEPATOLOGY (2007)

Add to Collection

Article Hematology

LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo

N Bovenschen et al.

BLOOD (2005)

Add to Collection

Article Multidisciplinary Sciences

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

KN Maxwell et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)

Add to Collection

Article Cardiac & Cardiovascular Systems

Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease

T Heitzer et al.

CIRCULATION (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.